K

    Kodiak Sciences Inc (KOD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $37.35
    -0.37 (-0.98%)

    Market Cap: $2.37B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(14/32)
    Avg Surprise
    -4.93%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.00
    Range$-1.07 - $-0.89
    5 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate Drift
    90d ago$-0.93+6.9%
    60d ago$-0.93+6.9%
    30d ago$-0.93+6.9%
    7d ago$-0.92+7.9%
    Current$-1.00
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.98
    Range$-1.07 - $-0.78
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.98---
    Sep 26EST
    		-$-1.00---
    Jun 26
    		$-1.05$-0.97-8.25%Miss-1.9%
    Mar 26
    		$-0.94$-1.01+6.93%Beat+13.8%
    Dec 25
    		$-1.04$-1.01-2.97%Miss-23.8%
    Sep 25
    		$-1.16$-1.04-11.54%Miss-38.1%
    Jun 25
    		$-1.03$-1.05+1.90%Beat-19.8%
    Mar 25
    		$-1.09$-0.87-25.29%Miss-32.9%
    Dec 24
    		$-0.84$-0.86+2.78%Beat+25.7%
    Sep 24
    		$-0.84$-0.90+6.67%Beat+11.6%
    Jun 24
    		$-0.86$-0.85-1.18%Miss+43.8%
    Mar 24
    		$-0.82$-1.06+22.64%Beat+39.3%
    Dec 23
    		$-1.13$-0.77-46.75%Miss+16.3%
    Sep 23
    		$-0.95$-1.35+29.63%Beat+35.4%
    Jun 23
    		$-1.53$-1.15-33.04%Miss+12.1%
    Mar 23
    		$-1.35$-1.37+1.46%Beat+26.2%
    Dec 22
    		$-1.35$-1.52+11.18%Beat+24.6%
    Sep 22
    		$-1.47$-1.71+14.04%Beat-13.1%
    Jun 22
    		$-1.74$-1.74+0.00%Beat-61.1%
    Mar 22
    		$-1.83$-1.56-17.31%Miss-86.7%
    Dec 21
    		$-1.79$-1.36-31.62%Miss-84.5%
    Sep 21
    		$-1.30$-1.18-10.17%Miss-62.5%
    Jun 21
    		$-1.08$-1.03-4.85%Miss-86.2%
    Mar 21
    		$-0.98$-0.98+0.00%Beat-81.5%
    Dec 20
    		$-0.97$-0.80-21.25%Miss-142.5%
    Sep 20
    		$-0.80$-0.70-14.29%Miss-142.4%
    Jun 20
    		$-0.58$-0.57-1.75%Miss-87.1%
    Mar 20
    		$-0.54$-0.46-17.39%Miss-157.1%
    Dec 19
    		$-0.40$-0.35-14.29%Miss-60.0%
    Sep 19
    		$-0.33$-0.33+0.00%Beat+13.2%
    Jun 19
    		$-0.31$-0.29-6.90%Miss+69.3%
    Mar 19
    		$-0.21$-0.37+43.24%Beat-
    Dec 18
    		$-0.25$-0.30+16.67%Beat-
    Sep 18
    		$-0.38$-0.26-46.15%Miss-
    Jun 18
    		$-1.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.91EV/EBITDA-0.12x
    Price/FCF-14.63xFCF Yield-6.84%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-368.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.49xQuick Ratio2.49x
    Trading Statistics
    Beta2.21Avg Volume592.80K
    52-Week High$47.8452-Week Low$8.29

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$38.91
    SMA 20$40.88
    SMA 50$40.23
    SMA 200$32.80
    EMA 10$38.97
    EMA 20$39.83
    EMA 50$39.73
    EMA 200$32.46

    MACD

    Line: -0.79Signal: -0.33Hist: -0.46

    ADX

    ADX: 23.0+DI: 12.6-DI: 29.1

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down100.0
    PSAR$42.97

    Bollinger Bands

    Upper Band$45.89
    Lower Band$35.87
    %B Position2449%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    40.5

    Momentum Oscillators

    Stoch %K21.8
    Stoch %D25.0
    Williams %R-80.0
    ROC (10d)-8.9%
    Momentum-3.63
    CCI (20d)-131.5
    MFI (14d)35.8

    Volatility Measures

    ATR (14d)$2.58(6.9%)
    StdDev (20d)2.50
    Hist Vol59.4%(High)

    Volume Flow

    VWAP$36.89
    OBV38.9M
    AD Line13.6M
    CMF (20d)0.061

    Volume Metrics

    Avg Vol (20d)593.5K
    Vol Ratio1.9x(High)
    VWMA (20d)$40.72

    Pivot Points

    R3$41.31
    R2$40.47
    R1$39.09
    Pivot Point$38.25
    S1$36.87
    S2$36.03
    S3$34.65

    Advanced Oscillators

    TSI-9.28
    Ultimate Osc46.9
    KST-44.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26.65M$0$0$0$0$0
    Cost of Revenue$0$0$-19,805,000$0$0$0$6.68M$0$0$0$6.66M$0
    Gross Profit$0$0$19.80M$0$0$0$-6,682,000$0$0$0$-6,664,000$0
    Operating Expenses$66.84M$59.78M$57.45M$62.35M$55.51M$59.07M$46.18M$46.63M$47.98M$46.05M$63.37M$54.50M
    R&D$56.08M$48.55M$45.49M$50.48M$42.76M$43.64M$31.77M$31.88M$32.51M$29.93M$46.63M$36.19M
    SG&A$10.76M$11.23M$11.96M$11.88M$12.75M$15.43M$14.41M$14.75M$15.47M$16.12M$16.75M$18.31M
    Operating Income$-66,838,000$-59,777,000$-57,453,000$-62,352,000$-55,510,000$-59,073,000$-46,179,000$-46,632,000$-47,983,000$-46,055,000$-63,374,000$-54,500,000
    Interest Income$1.25M$1.64M$757,000$917,000$1.24M$1.60M$2.13M$2.71M$2.95M$3.35M$3.90M$4.54M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$5,000
    Income Before Tax$-65,643,000$-58,158,000$-56,736,000$-61,457,000$-54,313,000$-57,461,000$-44,105,000$-43,946,000$-45,117,000$-43,039,000$-59,516,000$-50,007,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-65,643,000$-58,158,000$-56,736,000$-61,457,000$-54,313,000$-57,461,000$-44,105,000$-43,946,000$-45,117,000$-43,039,000$-59,516,000$-50,007,000
    EBITDA$-60,710,000$-53,459,000$-50,978,000$-55,835,000$-49,016,000$-52,335,000$-39,553,000$-39,960,000$-41,390,000$-39,746,000$-56,753,000$-47,568,000
    EBIT$-66,898,000$-59,799,000$-57,493,000$-62,374,000$-55,554,000$-59,063,000$-46,235,000$-46,657,000$-48,071,000$-46,392,000$-63,413,000$-54,538,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KOD

    News

    What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders

    Kodiak Sciences Inc. reported a widening net loss in Q2 2026 and for the first half of 2026, though its basic loss per share for H1 improved. The company, a pre-revenue biopharmaceutical firm, continues to rely on the success of its eye disease pipeline, particularly KSI-101 and Zenkuda, to offset its significant cash burn. Investors are closely watching trial milestones and the company's limited cash runway, which suggests a potential need for fresh capital.

    Simply Wall Street•8/26/26•
    Somewhat-Bearish

    HC Wainwright Lowers Earnings Estimates for Kodiak Sciences

    HC Wainwright has revised its Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences, lowering it to a loss of $0.89 from $0.80, while maintaining a "Buy" rating and a $58 price target. This adjustment follows Kodiak Sciences reporting a Q2 loss of $1.05 per share, which missed the consensus estimate. Despite the lowered estimates, the overall analyst consensus for Kodiak Sciences remains a "Moderate Buy" with an average target price of $48.14.

    MarketBeat•8/19/26•
    Neutral

    GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD

    GSA Capital Partners LLP acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, purchasing 27,525 shares valued at approximately $1.07 million. Institutional investors and hedge funds now own 89.06% of Kodiak Sciences stock. Analyst sentiment for the company is a "Moderate Buy" with an average price target of $48.14, despite missing recent quarterly earnings estimates.

    MarketBeat•8/18/26•
    Neutral

    H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58

    H.C. Wainwright has reiterated its Buy rating on Kodiak Sciences (KOD.US) and maintained a target price of $58. This indicates the firm's continued confidence in the company's prospects. Investors may find this analyst rating useful in their evaluation of Kodiak Sciences.

    Moomoo•8/18/26•
    Bullish

    KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58

    HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating for Kodiak Sciences (KOD), maintaining a price target of $58.00 despite the company's current stock price of $41.37. The company, which operates in the biotechnology sector and focuses on retinal medicines, has a low GF Score™ of 27/100, indicating areas for improvement in profitability and growth. Insider activity shows $1.0 million in selling over the last three months with no buying, and guru ownership is mixed.

    GuruFocus•8/17/26•
    Somewhat-Bullish

    Frequently Asked Questions About KOD

    Does KOD pay dividends?
    Kodiak Sciences Inc (KOD) does not currently pay a regular dividend.
    What is KOD's market cap?
    Kodiak Sciences Inc (KOD) has a market capitalization of $2.37B with a current stock price of $37.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In